AstraZeneca boosts cardiovascular-drug pipeline with AlphaCore buy

04/4/2013 | Reuters · American City Business Journals

AstraZeneca's MedImmune unit agreed to purchase AlphaCore Pharma, a privately held U.S. biotechnology firm, for an undisclosed amount. The acquisition gives AstraZeneca access to AlphaCore's ACP-501, a cholesterol-lowering drug candidate intended to reduce the risk of heart attack and stroke. The deal is expected to strengthen AstraZeneca's early-stage cardiovascular-drug pipeline.

View Full Article in:

Reuters · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations